Your browser doesn't support javascript.
loading
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill, Rebecca M; Kuijper, Sanne; Lindsey, Janet C; Petrie, Kevin; Schwalbe, Ed C; Barker, Karen; Boult, Jessica K R; Williamson, Daniel; Ahmad, Zai; Hallsworth, Albert; Ryan, Sarra L; Poon, Evon; Robinson, Simon P; Ruddle, Ruth; Raynaud, Florence I; Howell, Louise; Kwok, Colin; Joshi, Abhijit; Nicholson, Sarah Leigh; Crosier, Stephen; Ellison, David W; Wharton, Stephen B; Robson, Keith; Michalski, Antony; Hargrave, Darren; Jacques, Thomas S; Pizer, Barry; Bailey, Simon; Swartling, Fredrik J; Weiss, William A; Chesler, Louis; Clifford, Steven C.
Afiliación
  • Hill RM; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Kuijper S; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Lindsey JC; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Petrie K; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Schwalbe EC; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Barker K; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Boult JK; Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Williamson D; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Ahmad Z; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Hallsworth A; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Ryan SL; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Poon E; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Robinson SP; Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Ruddle R; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Raynaud FI; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Howell L; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Kwok C; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.
  • Joshi A; Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
  • Nicholson SL; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Crosier S; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Ellison DW; St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Wharton SB; Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.
  • Robson K; Children's Brain Tumour Research Centre, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2RD, UK.
  • Michalski A; Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.
  • Hargrave D; Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.
  • Jacques TS; Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK; Neural Development Unit, UCL Institute of Child Health, London WC1N 1EH, UK.
  • Pizer B; Oncology Unit, Alder Hey Children's Hospital, Liverpool L12 2AP, UK.
  • Bailey S; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • Swartling FJ; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala 751 85, Sweden.
  • Weiss WA; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center
  • Chesler L; Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK. Electronic address: louis.chesler@icr.ac.uk.
  • Clifford SC; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 4LP, UK. Electronic address: steve.clifford@ncl.ac.uk.
Cancer Cell ; 27(1): 72-84, 2015 Jan 12.
Article en En | MEDLINE | ID: mdl-25533335
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cerebelosas / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas c-myc / Meduloblastoma / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cerebelosas / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas c-myc / Meduloblastoma / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido